Joe McCann
Long/short equity, growth, medium-term horizon

Despite The Sell-Off, Zohydro Is A Falling Knife Too Dangerous To Catch

In my first Seeking Alpha article about Zogenix (NASDAQ:ZGNX), I outlined a potential pathway and precedent for the FDA to withdraw the marketing approval for Zogenix's Zohydro. For a full discussion of how I was not advocating for the drug's life in either direction you can check the comments, however; the point was purely that the FDA removed Oxycontin from the market to replace it with an abuse deterrent version. I was pointing out that the agency could do that again.

Over the past few months the FDA has come out and made a rather unprecedented, in my opinion, public effort to affirm their approval decision. FDA Commissioner Margaret Hamburg has blogged about her views on the drug...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details